Eric Dessertenne
Chief Executive Officer at BIOCORP
Profile
Eric Dessertenne is currently the Chief Executive Officer at BIOCORP Production SA since 2019.
He is also the Chairman at Aagie Sas and the Manager at Groupement foncier agricole René PATOU.
Previously, he served as the Chief Executive Officer at Brenus Pharma SAS.
Dr. Dessertenne holds an MBA from ESSEC Business School and an undergraduate degree from Université Blaise Pascal.
Eric Dessertenne active positions
Companies | Position | Start |
---|---|---|
BIOCORP | Chief Executive Officer | 2019-12-22 |
Groupement foncier agricole René PATOU | Corporate Officer/Principal | - |
Aagie Sas | Chairman | - |
Former positions of Eric Dessertenne
Companies | Position | End |
---|---|---|
Brenus Pharma SAS
Brenus Pharma SAS Miscellaneous Commercial ServicesCommercial Services Brenus Pharma SAS is a French company that has developed an allogeneic platform to generate first in class immune therapy to prevent cancer resistance over treatment. The company is based in Issoire, France. The company's technology, stc10-10, targets mss and msi-h population with a robust and validated preclinical data pack to offer an off-the-shelf technology allowing control of both time and cost of the manufacturing process. Brenus Pharma aims to harness a specific, highly potent, and durable immune response against moving targets in cancer by claiming the representativity, the antigenicity, and the immunogenicity of its solution. The company was founded by Benoit Pinteur, Jacques Gardette. The CEO is Paul Bravetti. | Chief Executive Officer | - |
Training of Eric Dessertenne
ESSEC Business School | Masters Business Admin |
Université Blaise Pascal | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BIOCORP | Health Technology |
Private companies | 3 |
---|---|
Brenus Pharma SAS
Brenus Pharma SAS Miscellaneous Commercial ServicesCommercial Services Brenus Pharma SAS is a French company that has developed an allogeneic platform to generate first in class immune therapy to prevent cancer resistance over treatment. The company is based in Issoire, France. The company's technology, stc10-10, targets mss and msi-h population with a robust and validated preclinical data pack to offer an off-the-shelf technology allowing control of both time and cost of the manufacturing process. Brenus Pharma aims to harness a specific, highly potent, and durable immune response against moving targets in cancer by claiming the representativity, the antigenicity, and the immunogenicity of its solution. The company was founded by Benoit Pinteur, Jacques Gardette. The CEO is Paul Bravetti. | Commercial Services |
Groupement foncier agricole René PATOU | |
Aagie Sas |
- Stock Market
- Insiders
- Eric Dessertenne